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Background: Approximately 50% of patients with heart failure (HF) have a preserved ejection fraction (HFpEF). Diabetes mellitus (DM) is common 
in HFpEF and its presence may be associated with worse outcomes.
methods and results: The I-Preserve (Irbesartan in Heart Failure with Preserved Ejection Fraction) trial randomized 4128 patients with HFpEF 
to placebo or irbesartan (60% female, mean age 71.6 +/- 6.9 years). There were 1134 patients (27.5%) with DM by baseline history, of which 314 
(27.7%) died, and 722 (63.7%) had at least one hospitalization of any type. Of the 2994 (72.5%) without DM, 567 (18.9%) died and 1556 (52.0%) 
had at least one hospitalization of any type. In multivariable adjusted Cox proportional hazards models, patients with DM had a 50-100% higher risk 
of the primary outcome (all-cause mortality or hospitalization for cardiovascular (CV) cause), HF composite (HF death or HF hospitalization), and 
major types of death versus those without DM (Table). The risk of hospitalization for non-CV and some CV causes (HF, MI and unstable angina) was 
between 35-75% higher in diabetics. There was no difference in the rate of hospitalization for stroke or arrhythmias. Irbesartan had no significant 
effect on death or hospitalization among DM or non-DM patients.
conclusions: DM was common in the I-PRESERVE cohort of patients with HFpEF and was associated with significantly higher rates of death and 
hospitalization, but no difference in the rate of hospitalization for stroke, atrial or ventricular arrhythmias. 
No DM (n=2994, 72.5%) DM (n=1134, 27.5%) DM vs Non-DM*
Patients with Event (%) Rate/100PY Patients with Event (%) Rate/100PY HR (95% CI) P
Main trial outcomes
Primary composite outcome 985 (32.9) 8.98 520 (45.9) 14.19 1.52 (1.35-1.71) < 0.001
All-cause mortality 567 (18.9) 4.56 314 (27.7) 7.18 1.61 (1.38-1.88) < 0.001
Heart failure composite 440 (14.7) 3.81 276 (24.3) 7.21 1.77 (1.49-2.09) < 0.001
Cause specific mortality
Heart failure death 72 (2.4) 0.58 53 (4.7) 1.21 2.02 (1.36-2.99) 0.001
Sudden death 144 (4.8) 1.16 87 (7.7) 1.99 1.74 (1.30-2.33) < 0.001
Any CV death 344 (11.5) 2.77 188 (16.6) 4.30 1.55 (1.28-1.89) < 0.001
Non CV death 174 (5.8) 1.40 94 (8.3) 2.15 1.65 (1.25-2.19) < 0.001
Cause specific hospitalization
Non-Cardiovascular 938 (31.3) 9.05 454 (40.0) 13.5 1.42 (1.25-1.61) < 0.001
Any-Cardiovascular 1103 (36.8) 11.2 529 (46.7) 16.6 1.34 (1.19-1.51) < 0.001
Heart failure 423 (14.1) 3.66 262 (23.1) 6.84 1.75 (1.47-2.08) < 0.001
Myocardial infarction 99 (3.3) 0.81 55 (4.9) 1.28 1.57 (1.09-2.27) 0.016
Unstable angina 106 (3.5) 0.87 58 (5.1) 1.37 1.43 (1.00-2.06) 0.052
Stroke 141 (4.7) 1.15 59 (5.2) 1.37 1.06 (0.75-1.49) 0.738
Atrial arrhythmia 127 (4.2) 1.05 48 (4.2) 1.13 1.03 (0.70-1.52) 0.880
Ventricular arrhythmia 10 (0.3) 0.08 3 (0.3) 0.07 0.51 (0.11-2.37) 0.390
*Adjusted for baseline NT-pro-BNP, Age, LVEF, HR, Neutrophils, HF hosp within 6mo, COPD/asthma, GFR, Ischemic etiology, h/o of MI.
